MaxCyte (MXCT) has released an update.
MaxCyte, Inc., a leader in cell-engineering technology, has announced the publication of its Annual Report and Accounts for the year ended December 31, 2023. The report, which highlights MaxCyte’s advancements in cell-based research and therapy development, is available on the company’s website. The firm’s ExPERT platform is emphasized as a key driver in supporting the growth of next-generation cell therapies.
For further insights into MXCT stock, check out TipRanks’ Stock Analysis page.
